Drugs watchdog condemns Roche for high price of breast cancer therapy

February 19, 2016 by Prof. Sullivan in

The pharmaceuticals giant Roche has been criticised in unprecedented terms by the government’s drugs watchdog for refusing to significantly lower the price of a breast cancer drug whose £90,000-per-patient cost is well over the NHS’s limit.

The National Institute for Health and Care Excellence (Nice), says it cannot recommend the drug, Kadcyla, which promises extra months of life for women with advanced breast cancer, because of Roche’s inflexibility.

Best Blogs
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
#
March 10, 2015
March 10, 2015
Best Blogs Container